Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Completed 38 Terminated 21 Recruiting 18 Unknown 11 Withdrawn 9 Active not recruiting 6 Not yet recruiting 4 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 3 Drug Therapy 3 Vincristine 2 S 1 (combination) 2 Nivolumab 2 Gemcitabine 2 Cyclophosphamide 2 CA-4948 2 Bevacizumab 2 zimberelimab 1 venetoclax 1 tivozanib 1 titanium silicide 1 tisagenlecleucel 1 sotigalimab 1 propranolol CR 1 prednylidene 1 pimonidazole 1 palbociclib 1 mirdametinib 1 imisopasem manganese 1 gusacitinib 1 fludarabine 1 deltacortene 1 brincidofovir 1 axicabtagene ciloleucel 1 atezolizumab 1 Testosterone Propionate 1 Testosterone 1 Temozolomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Suspended × 130-nm albumin-bound paclitaxel × Clear all

NCT03417921 2025-10-01

Pancreatic

Ability Pharmaceuticals SL

Phase 1/2 Suspended

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡